On November 11, Lou Jingwei, the chairman of Shanghai Biotecan Pharmaceuticals Co., Ltd. (hereinafter referred to as Shanghai Biotecan Pharmaceuticals), visited Yunnan Dian Zhong New Area and held a meeting with the Management Committee of Yunnan Dian Zhong New Area to have an in-depth discussion on the cooperation in order to let the project settle in the New Area as soon as possible.

During the meeting, Zhao Xuefeng, the Deputy Secretary of the Party Working Committee and the Deputy Director of the Management Committee of Yunnan Dian Zhong New Area, said that Yunnan Dian Zhong New Area is vigorously developing the biomedical industry. On the basis of the policy on investment attraction, Yunnan Dian Zhong New Area introduced a special policy to promote the high-quality development of the biomedical sector, which is competitive among current domestic policies so as to create a favorable policy environment for industrial development. At present, China's pharmaceutical and health industries have been developing on a fast track. It is hoped that Shanghai Biotecan Pharmaceuticals can carry out large projects here and join hands with Yunnan Dian Zhong New Area to build a cutting-edge diagnostic public service platform, major industry innovation platforms of life science and technology, construct an industrial innovation ecology and jointly create a leading high-end medical device industry cluster in the region by giving full play to the advantages of technology, management, and resources of Shanghai Biotecan Pharmaceuticals.

After Lou Jingwei visiting the planning exhibition hall of Yunnan Dian Zhong New Area, airport industrial park, intelligent equipment industrial park, and Talent Condos, and learning in detail about the spatial planning, economic development, industry support, and talent policies of Yunnan Dian Zhong New Area, Lou said that Yunnan Dian Zhong New Area has advantages in terms of policies, location and transportation and huge space for future development. It is hoped that this visit will be an opportunity to help accelerate projects to settle in Yunnan Dian Zhong New Area and create digital medical innovation laboratories with global influence in the New Area. Meanwhile, it is also hoped to build a leading digital medical industry ecology, integrate resources of universities, hospitals, and international industries and promote the transformation of technological innovation products; construct domestic leading digital medical industry clusters with strong economic and social benefits, bring together international leading digital medical innovation projects and teams, and push forward a number of projects to grow into unicorn companies so as to help promote the industrial development of Yunnan Dian Zhong New Area. (Editors: Ines, Rachel)